185 related articles for article (PubMed ID: 22334239)
1. Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin.
Shi G; Chen X; Wang H; Wang S; Guo X; Zhang X
J Antibiot (Tokyo); 2012 May; 65(5):229-36. PubMed ID: 22334239
[TBL] [Abstract][Full Text] [Related]
2. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
Seral C; Barcia-Macay M; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2005 Apr; 55(4):511-7. PubMed ID: 15731197
[TBL] [Abstract][Full Text] [Related]
3. Factors compromising the activity of moxifloxacin against intracellular Staphylococcus aureus.
Nguyen HA; Grellet J; Dubois V; Saux MC; Quentin C
J Antimicrob Chemother; 2007 Apr; 59(4):755-8. PubMed ID: 17353222
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium.
Sano C; Tatano Y; Shimizu T; Yamabe S; Sato K; Tomioka H
Int J Antimicrob Agents; 2011 Apr; 37(4):296-301. PubMed ID: 21353489
[TBL] [Abstract][Full Text] [Related]
5. Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and Listeria monocytogenes.
Van de Velde S; Nguyen HA; Van Bambeke F; Tulkens PM; Grellet J; Dubois V; Quentin C; Saux MC
J Antimicrob Chemother; 2008 Sep; 62(3):518-21. PubMed ID: 18544595
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
7. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Hesje CK; Borsos SD; Blondeau JM
J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
[TBL] [Abstract][Full Text] [Related]
8. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
Shandil RK; Jayaram R; Kaur P; Gaonkar S; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Balasubramanian V
Antimicrob Agents Chemother; 2007 Feb; 51(2):576-82. PubMed ID: 17145798
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing the intracellular activity of fluoroquinolones: a study using levofloxacin in a Staphylococcus aureus THP-1 monocyte model.
Nguyen HA; Grellet J; Paillard D; Dubois V; Quentin C; Saux MC
J Antimicrob Chemother; 2006 May; 57(5):883-90. PubMed ID: 16533826
[TBL] [Abstract][Full Text] [Related]
10. Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial.
Farrell DJ; Turner LL; Castanheira M; Jones RN
Diagn Microbiol Infect Dis; 2012 Sep; 74(1):73-4. PubMed ID: 22819242
[TBL] [Abstract][Full Text] [Related]
11. High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy.
Murillo O; Pachón ME; Euba G; Verdaguer R; Tubau F; Cabellos C; Cabo J; Gudiol F; Ariza J
J Infect; 2009 Mar; 58(3):220-6. PubMed ID: 19217166
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP
Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004
[TBL] [Abstract][Full Text] [Related]
13. Intracellular antimicrobial activity appearing as a relevant factor in antibiotic efficacy against an experimental foreign-body infection caused by Staphylococcus aureus.
Murillo O; Pachón ME; Euba G; Verdaguer R; Carreras M; Cabellos C; Cabo J; Gudiol F; Ariza J
J Antimicrob Chemother; 2009 Nov; 64(5):1062-6. PubMed ID: 19744977
[TBL] [Abstract][Full Text] [Related]
14. Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages.
Vallet CM; Marquez B; Ngabirano E; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
Int J Antimicrob Agents; 2011 Sep; 38(3):249-56. PubMed ID: 21764262
[TBL] [Abstract][Full Text] [Related]
15. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination.
Firsov AA; Vostrov SN; Lubenko IY; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2004 May; 23(5):451-6. PubMed ID: 15120722
[TBL] [Abstract][Full Text] [Related]
16. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F;
Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
[TBL] [Abstract][Full Text] [Related]
17. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Sierra JM; Cabeza JG; Ruiz Chaler M; Montero T; Hernandez J; Mensa J; Llagostera M; Vila J
Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
[TBL] [Abstract][Full Text] [Related]
18. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
D'Arienzo PA; Wagner RS; Jamison T; Bell B; Dajcs JJ; Stroman DW
Adv Ther; 2010 Jan; 27(1):39-47. PubMed ID: 20174904
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae.
Lemmen SW; Häfner H; Klik S; Lütticken R; Zolldann D
Chemotherapy; 2003 May; 49(1-2):33-5. PubMed ID: 12714807
[TBL] [Abstract][Full Text] [Related]
20. In-vitro activity of quinupristin/dalfopristin, levofloxacin and moxifloxacin against fusidic acid and rifampicin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA) from Malaysian hospitals.
Norazah A; Lim VK; Rohani MY; Kamel AG
Med J Malaysia; 2005 Oct; 60(4):411-5. PubMed ID: 16570701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
